Related Experiment Videos
[Statins: possibly more than just lowering of the lipid level]
F L Visseren1, P J Lansberg, D W Erkelens
1Afd. Inwendige en Vasculaire Geneeskunde, Universitair Medisch Centrum, Utrecht. F.Visseren@digd.azu.nl
Insights
HMG-CoA reductase inhibitors (statins) offer vascular benefits beyond cholesterol reduction. These non-lipid effects, including plaque stabilization and improved endothelial function, contribute to preventing vascular diseases.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Context:
- Hypercholesterolemia treatment with statins is proven effective for vascular disease prevention.
- Observed reductions in cardiovascular morbidity and mortality exceed lipid-lowering effects alone.
Purpose:
- To explore the non-lipid-lowering mechanisms of statins contributing to vascular protection.
- To elucidate how statins influence vascular wall properties beyond cholesterol reduction.
Summary:
- Statins exert pleiotropic effects on the vascular wall, including improving endothelial function via nitric oxide synthesis.
- They stabilize atherosclerotic plaques by inhibiting macrophage infiltration and matrix metalloproteinase production.
- Statins reduce leukocyte adhesion, thereby inhibiting atherosclerosis initiation and progression.
- Furthermore, statins enhance fibrinolytic capacity and inhibit tissue factor expression, reducing hemorrhagic diathesis.
Impact:
- These non-lipid mechanisms of statins may significantly contribute to the primary and secondary prevention of vascular events.
- Further research is needed to determine the clinical relevance of these pleiotropic effects in vivo.
Abstract:
Clinical trials have demonstrated that treatment of hypercholesterolemia with HMG-CoA reductase inhibitors (statins) is beneficial in primary and secondary prevention of vascular diseases. The observed reduction in cardiovascular morbidity and mortality cannot only be explained by lipid-lowering only. Apart from lowering cholesterol, statins conceivably also exert effects on the vascular wall that may directly contribute to decrease of vascular incidents: (a) a favourable influence on endothelial dysfunction through stimulation of nitrous oxide synthetase: (b) stabilization of plaques by reducing influx of macrophages into the vascular wall and decreasing the production of matrix metalloproteinases, that may affect the connective tissue cover of the plaque: (c) inhibition of the initiation and progression of atherosclerosis by reducing adhesion of leukocytes to the vascular wall: (d) reducing the haemorrhagic diathesis by increasing the fibrinolytic capacity and inhibiting tissue factor expression on macrophages. All these effects of statins independent of the lowering of the cholesterol level might contribute to primary and secondary prevention of vascular incidents. While most nonlipid mechanisms of statins are being studied in vitro and in animals, the clinical relevance is still to be determined.